Cardiovascular Diseases, Coronary Aneurysm, Heart Diseases, Infection
Conditions
Brief summary
The primary endpoint is coronary artery diameter, normalized for body surface area, 5 weeks after randomization. Secondary endpoints include duration of fever, CRP levels, and adverse events.
Detailed description
BACKGROUND: Kawasaki Disease (KD) is an inflammatory vasculitis of unknown etiology that affects infants and children and can cause coronary artery aneurysms. Standard therapy consists of 2 gm/kg of intravenous immune globulin plus high-dose aspirin in the acute phase, and low-dose aspirin in the convalescent phase. Some children do not respond to this therapy, and some children go on to develop coronary artery aneurysms in spite of aggressive treatment. This led to the design of this randomized controlled trial to compare a single dose of intravenous steroids vs. placebo on the background of standard therapy. Recruitment began in December, 2002 and ended in December, 2004 with nearly 200 patients randomized. DESIGN NARRATIVE: This is a randomized controlled trial to compare a single dose of intravenous steroids vs. placebo on the background of standard therapy
Interventions
DRUGSteroids
This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Pediatric Heart Network
Carelon Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Fever persisting at least 4 days and the presence of at least 4 of the following 5 principal features: 1. Changes in extremities: Acute changes include erythema and edema of hands and feet; Convalescent changes include membranous desquamation of fingertips 2. Polymorphous exanthema 3. Bilateral, painless bulbar conjunctival injection without exudates 4. Changes in lips and oral cavity: Erythema and cracking of lips, strawberry tongue, diffuse injection of oral and pharyngeal mucosae 5. Cervical lymphadenopathy ( 1.5 cm in diameter), usually unilateral; OR * Patients with at least four days of fever and coronary artery disease, defined as either: 1\. Having a z-score in either the proximal right coronary artery or the proximal left anterior descending coronary artery of \> 2.5 detected by 2-dimensional echocardiography, as well as: * For patients under six months of age, at least two principal criteria * For patients at least six months of age, at least three principal criteria. 2. Meeting Japanese Ministry of Health criteria for coronary aneurysm defined as an internal lumen diameter of \>3 mm in children less than 5 years of age or \>4 mm in children 5 years of age and older, in either the proximal right coronary artery or the proximal left anterior descending coronary artery and at least one principal criterion. AND Enrollment within ten days of the onset of illness, with Day 1 defined as the first day of fever AND Informed consent of parents and assent of children who are older than age 7 years and capable of understanding or according to institutional guidelines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare the effect of IVMP plus IVIG to IVIG alone on coronary artery outcomes | Measured 5 weeks post-randomization |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of CA aneurysms; individual z scores of the LMCA, proximal RCA, and proximal LAD CA at 1 and 5 weeks; changes in absolute coronary dimensions for all CA segments from baseline to 1 and 5 weeks after randomization | Measured 5 weeks post-randomization |
Outcome results
None listed